Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients
ObjectivesHyperkalemia most commonly develops in chronic kidney disease (CKD) or heart failure (HF) patients. Sodium zirconium cyclosilicate (SZC) is a new selective potassium (K+) binder for treating hyperkalemia. The aim of this study was to evaluate the cost-effectiveness of SZC vs. usual care fo...
Saved in:
Main Authors: | Lei Tian (Author), Shihui Fu (Author), Mengyuan Li (Author), Xinrui Zhao (Author), Hongchao Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Letter to the editor regarding ''Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia'
by: Donna Zarzuela, PharmD, et al.
Published: (2021) -
Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
by: Dhan Bahadur Shrestha, MD Resident Physician, et al.
Published: (2021) -
Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study
by: Agiro A, et al.
Published: (2023) -
Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study)
by: Nan Shen, et al.
Published: (2024) -
Advancing crush syndrome management: the potent role of Sodium zirconium cyclosilicate in early hyperkalemia intervention and survival enhancement in a rat model
by: Duo Li, et al.
Published: (2024)